A growing share of Americans are walking into restaurants with smaller appetites than they had two years ago, and it has nothing to do with diet fads or economic caution. It has to do with a pill or an injection. Gallup’s most recent survey, conducted in late May and early June 2026 among more than five thousand U.S. adults, found that 11% of the population now takes a GLP-1 medication for weight loss, up from just 3% in 2024. That kind of growth in two years is rare for any consumer behavior tied to a prescription drug.
The reach goes further than individual users. According to PwC’s analysis of Numerator purchase data, about one in five U.S. households, 21%, now includes a current GLP-1 user, more than double the 9% recorded in January 2025. For a restaurant operator, that means roughly every fifth table seated on a given night may include a guest whose appetite is being actively suppressed by medication, whether the server notices or not.
The behavioral pattern is fairly consistent wherever researchers have looked. GLP-1 users eat about 21% fewer calories on average and spend close to a third less on food overall, a shift that touches groceries and restaurant visits alike. They are not skipping meals so much as ordering smaller ones, skipping appetizers and dessert, and leaning toward high protein dishes instead of the snacks and sweets that used to round out a check. None of this shows up as a complaint or a bad review. It shows up later, in a slightly smaller average ticket that is easy to blame on the economy when the real cause is sitting at the table.
J.P. Morgan’s Global Research team estimates the shift will cost the food and beverage industry between $30 billion and $55 billion in annual revenue between 2030 and 2034 (J.P. Morgan). Circana projects that GLP-1 households will account for 35% of all food and beverage units sold by 2030, a number large enough to reshape category performance across the industry rather than nibble at its edges.
Restaurant chains have started to respond in different ways. Chipotle Mexican Grill (NYSE: CMG) introduced a High Protein Menu that adds extra protein options across its bowls and burritos. Starbucks (NASDAQ: SBUX) has built protein into close to 90% of its drink lineup, according to reporting from Axios. Shake Shack (NYSE: SHAK) and Subway have each rolled out protein dense, portion controlled items of their own. Not every chain is moving in the same direction, though. Brinker International (NYSE: EAT), the parent of Maggiano’s Little Italy, increased pasta portions by roughly 20% and expanded its family style menu without raising prices, betting that abundance can be a point of difference in a market where portions everywhere else are shrinking.
The packaged food side of the business is adjusting too. General Mills (NYSE: GIS) and Nestlé (SIX: NESN) have both reformulated products aimed specifically at GLP-1 users, part of a broader effort among food manufacturers to hold onto a customer base that is eating less overall.
There is a wrinkle worth keeping in mind before anyone treats this as a settled trend. Between 50% and 75% of GLP-1 users discontinue the medication within their first year, according to research cited by Northwestern University. PwC’s own 2026 survey found that 54% of current users have stayed on the drugs for more than a year, up from 38% in 2024, which suggests the population that remains is becoming more established even as new users continue to cycle in and out. The user base is expanding and churning at the same time, and operators who read too much into any single quarter’s numbers risk overcorrecting.
For independent operators without a national data team, the response does not require a full menu overhaul. Pulling twelve months of point-of-sale data on appetizer, dessert, and beverage attach rates, then comparing that against average check trends, is usually enough to show whether GLP-1 behavior is already showing up in the numbers. A protein callout here, a smaller portion option there, tends to matter more than any single sweeping change.
What makes this shift different from the diet trends restaurants have absorbed before is that it does not ask permission. A gluten free menu section can be added or dropped depending on demand. A pharmaceutical appetite cannot be negotiated with, and it does not go back to normal once a guest sits down at a table. The operators who will come out ahead are not necessarily the ones with the biggest marketing budgets or the flashiest new menu items. They are the ones willing to look honestly at their own sales data now, while the shift is still showing up as a few percentage points here and there, rather than waiting until it shows up as a headline they did not see coming.
